The EBV vaccine, and what's coming
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
No EBV vaccine is approved. That is a straightforward answer to a question people increasingly ask, usually after reading about the MS link.
What makes this field interesting is what a vaccine might prevent: not only mono, but potentially a share of MS cases and several cancers. That is a large prize and it is why serious money is now behind it.
Related pages: Epstein-Barr virus (EBV) infection · Mononucleosis (mono)
The bottom line
- No EBV vaccine is currently approved anywhere.
- Several candidates are in early clinical trials.
- Existing antivirals reduce shedding but do not clear latent EBV.
- EBV-specific T cell therapies are used in specific high-risk situations.
- Whether a vaccine can prevent infection rather than only preventing mono.
- Whether preventing EBV would reduce MS incidence, which would take many years to show.
The story, step by step
What the evidence labels mean
A virus built to persist
What happens
EBV has features that make vaccine design difficult.
What the research shows
- It establishes lifelong latency in memory B cells, hiding from immune surveillance in a cell type the immune system is reluctant to destroy.
- It enters two different cell types, B cells and epithelial cells, using different combinations of surface proteins, so blocking one route may not block the other.
- It carries genes that interfere with immune recognition.
- Natural infection does not prevent reinfection with other strains, which means natural immunity is not a straightforward template to copy.
- The bar is also unusually high: preventing an infection that most people get silently in childhood, in order to prevent diseases that appear decades later.
Why it matters
The design problem is not just stimulating antibodies, it is stopping a virus that has evolved specifically to establish permanent residence.
What's still uncertain
- Whether sterilizing immunity against EBV is achievable is not known.
Read more
- NIAID: Epstein-Barr virus researchGovernment
- CDC: About Epstein-Barr virusGovernment
Next: The targets
gp350 and the fusion complex
What happens
What the candidate vaccines aim at.
What the research shows
- gp350 is the main protein EBV uses to attach to B cells, and it was the earliest target. A gp350 vaccine tested years ago reduced symptomatic mono without preventing infection.
- That result is informative: preventing illness may be achievable even if preventing infection is not.
- Newer candidates target the fusion machinery, gH, gL, gp42 and gB, which the virus needs to enter both B cells and epithelial cells.
- Combination approaches aim at several targets at once, to block both entry routes.
- Nanoparticle designs, displaying many copies of a protein on a single particle, produce stronger antibody responses than the protein alone.
Why it matters
A vaccine that prevented mono without preventing infection would still be valuable, since symptomatic mono carries the higher MS risk.
What's still uncertain
- Which target or combination will work best is unresolved.
Read more
- NIAID: Epstein-Barr virus researchGovernment
- CDC: About Epstein-Barr virusGovernment
Next: Where it stands
In trials
What happens
The current state, as of this page's review date.
What the research shows
- Several candidates have entered human trials, including mRNA vaccines, which use the same platform as the COVID vaccines, and protein nanoparticle designs.
- These are early-phase trials, assessing safety and immune response rather than whether disease is prevented.
- Proving that a vaccine prevents MS would require following vaccinated people for many years, since MS appears decades after infection.
- A more achievable first goal is preventing infectious mononucleosis in adolescents, which can be measured within a few years.
- Nothing is available outside trials, and anything sold as an EBV vaccine or EBV immunization is not one.
Why it matters
The realistic near-term target is preventing mono. Preventing MS, if it happens at all, is a much longer answer.
What's still uncertain
- Trial results are still emerging and timelines are uncertain.
Read more
- NIAID: Epstein-Barr virus researchGovernment
- OwieClear: Does the mono virus cause MS?OwieClear
Next: Antivirals
What they do and don't do
What happens
The drugs that exist, and their limits.
What the research shows
- Acyclovir and valacyclovir act against actively replicating herpesviruses, and they do reduce EBV shedding in saliva.
- They do not shorten mono, do not improve symptoms, and are not recommended for it.
- They have no effect on latent EBV, because the latent virus is not replicating and so offers these drugs nothing to act on.
- This is why there is no cure for carrying EBV, and why courses of antivirals prescribed for chronic EBV do not deliver what is promised.
- They do have roles in specific situations in immunosuppressed patients, directed by specialists.
Why it matters
If someone offers an antiviral course to clear EBV, that is not something these drugs can do.
What's still uncertain
- Whether newer antivirals targeting latency could work is being studied.
Read more
- CDC: About infectious mononucleosisGovernment
- NIAID: Epstein-Barr virus researchGovernment
Next: What is being tried
Cell therapy and beyond
What happens
Treatments aimed at EBV-driven disease rather than at ordinary infection.
What the research shows
- EBV-specific T cell therapy grows immune cells that recognize EBV and gives them to patients with EBV-driven disease after transplantation, with good results in that setting.
- A version of this has been studied in MS, on the theory that EBV-infected B cells contribute to the disease. Results are early.
- EBNA1 inhibitors, small molecules targeting a protein the virus needs to maintain latency, are in development.
- B cell depleting drugs used in MS remove the cells EBV lives in, which is one proposed explanation for why they work so well.
- None of this is available outside trials and specialist settings, and none of it is relevant to ordinary EBV carriage.
Why it matters
This is a genuinely active research field. It is also years away from anything a person with mono or post-viral fatigue could use.
What's still uncertain
- These are early-stage approaches and most will not reach clinical use.
Read more
- NIAID: Epstein-Barr virus researchGovernment
- OwieClear: Multiple sclerosis (MS)OwieClear
More plain-language reading
- OwieClear: Can EBV be prevented?OwieClear
- OwieClear: What EBV is linked toOwieClear
- OwieClear: Does the mono virus cause MS?OwieClear